A pharmacoeconomic analysis of the use of single MMC instillation in low risk NMIBC in Italy

Renzo Colombo, Federico Pellucchi, Lorenzo Rocchini, Carmen Maccagnano, Pablo Katz, Valeria Pegoraro

DOI: https://doi.org/10.7175/fe.v14i1.635


BACKGROUND: Bladder cancer accounts for 5-10% of all cancers in Europe and up to 85% patients presents a noninvasive tumor, whose treatment of choice is the transurethral bladder resection (TURB) paired with adjuvant intravesical chemotherapy or immunotherapy. Despite several clinical trials showed that this treatment is safe and decreases recurrences by 17% to 44% this practice is limited for many reasons. The study objective is to analyze the economical advantages of the single immediate post operative Mitomycin C instillation in Non Muscle-invasive Bladder Cancer (NMIBC) low-risk patients.
METHODS: A cost-benefit analysis was performed evaluating the economical gain that would raised from a scenario with a single immediate post operative mitomycin C instillation in each low-risk NMIBC patient who underwent to TURB. Net present value and cost-benefit ratio were calculated and sensitivity analyses were performed. Base case analysis was performed considering tumor recurrence rate reduction of 11.7% and a TURB costs of 2,167.0 €, while sensitivity analyses were performed using a recurrence rate reduction of 19.2% and 15.0% and a TURB cost of 2,472.93 €. The discount rate was 2%.
RESULTS: The single immediate post operative instillation of mitomycin C resulted to be cost-beneficial with a cost-benefit ratio that goes from 0.48 to 0.79 when compared to TURB alone raising a Net Present Value that goes from 660,284.39 € to 2,650,530.79 €.
CONCLUSION: This study demonstrates that even assuming conservative parameters for recurrence rates reduction, a single immediate post operative mitomycin C instillation in low risk NMIBC patients would lower not only the recurrence rate but also the caring cost for bladder cancer.


Low risk NMIBC; TURB; Mitomycin C; Cost-benefit analysis; Single dose instillation

Full Text:



  • Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34; http://dx.doi.org/10.1016/j.urology.2005.07.062
  • Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents. Lyon: IARC Publications, 2002
  • Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108; http://dx.doi.org/10.3322/canjclin.55.2.74
  • van der Heijden AG, Witjes JA. Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer. Eur Urol 2009; 8(suppl): 556-62; http://dx.doi.org/10.1016/j.eursup.2009.06.010
  • Oosterlinck W, Lobel B, Jakse G, et al. The EAU Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002; 41: 105-12; http://dx.doi.org/10.1016/S0302-2838(01)00026-4
  • Solsona E, Iborra I, Ricos JV, et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999; 161: 1120-3; http://dx.doi.org/10.1097/00005392-199904000-00018; http://dx.doi.org/10.1016/S0022-5347(01)61606-9
  • Burnand KG, Boyd PJ, Mayo ME, et al. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 1976; 48: 55-9; http://dx.doi.org/10.1111/j.1464-410X.1976.tb02742.x
  • Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149: 749-52
  • Ali-el-Dein B, Nabeeh A, el-Baz M, et al. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 1997; 79: 731-5; http://dx.doi.org/10.1046/j.1464-410X.1997.00142.x
  • Shuin T, Kubota Y, Noguchi S, et al. A phase II study of prophylactic intravesical chemotherapy with 4’-epirubicin in recurrent superficial bladder cancer: comparison of 4’-epirubicin and Adriamycin. Cancer Chemother Pharmacol 1994; 35(suppl): S52-6; http://dx.doi.org/10.1007/BF00686920
  • Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996; 155: 1233-8; http://dx.doi.org/10.1097/00005392-199604000-00023; http://dx.doi.org/10.1016/S0022-5347(01)66226-8
  • Cohen FJ, Neslusan CA, Conklin JE, et al. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003; 26: 1847-51; http://dx.doi.org/10.2337/diacare.26.6.1847
  • Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996; 47: 169-78; http://dx.doi.org/10.1016/S0090-4295(99)80410-5
  • Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005; 8: 149-56; http://dx.doi.org/10.1111/j.1524-4733.2005.03089.x
  • Madeb R, Golijanin D, Noyes K, et al. Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 2009; 115: 2660-70; http://dx.doi.org/10.1002/cncr.24311
  • Italian Central Bank. 2010. Available at: www.bancaditalia.it
  • Ministry of Health. Annual Report on Hospitalization activities. Data from 2010 Hospital Discharge Forms (SDO). Italy. Available at: http://www.salute.gov.it/ricoveriOspedalieri/ricoveriOspedalieri.jsp
  • Sylvester R, Oosterlinck W, Van der Meijden A. A single immediate post-operative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: A Meta-Analysis of published results of randomized clinical trials. J Urol 2004. 171: 2186-90; http://dx.doi.org/10.1097/01.ju.0000125486.92260.b2
  • Racioppi M, Volpe A, Falabella R, et al. The cost of treatment and follow-up of bladder cancer in Italy. Arch Ital Urol Androl 2007; 79: 111-7
  • National Statistic Institutes (ISTAT). FOI(nt) – National Prices Indexes for employees families (2011). Italy. Available at: www.istat.it
  • National Agency for Regional Healthcare Services (Agenas). 2010. Hospital Discharges (2009). Available at: http://www.agenas.it/monitoraggio_costi_tariffe/2009_SistemiTariffariRicoveri.pdf
  • El-Ghobashy S., El-Leithy TR, Roshdy MM, et al. Effectiveness of a single immediate Mitomycin C instillation in patients with low risk superficial bladder Cancer: Short and Long-Term Follow-up. J Egypt Natl Canc Inst 2007; 19: 121-6
  • Mencacci C, Di Sciascio G, Katz P, et al. A cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy. Clinicoecon Outcomes Res 2013; 5: 87-99


  • There are currently no refbacks.

© SEEd srl